This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cerebral Blood Flow Effects of Resveratrol and Piperine in Humans

This study has been completed.
Sponsor:
Information provided by:
Northumbria University
ClinicalTrials.gov Identifier:
NCT01331382
First received: April 6, 2011
Last updated: April 7, 2011
Last verified: April 2011
April 6, 2011
April 7, 2011
April 2010
November 2010   (Final data collection date for primary outcome measure)
  • Modulation of levels of total haemoglobin [ Time Frame: 80 minutes following treatment administration ]
  • Modulation of levels of deoxygenated haemoglobin [ Time Frame: 80 minutes following treatment administration ]
  • Modulation of levels of oxygenated haemoglobin [ Time Frame: 80 minutes following treatment administration ]
Same as current
No Changes Posted
Number of participants displaying significant modulation of cognitive performance [ Time Frame: 40-80 minutes post dose ]
Cognitive performance was assessed at baseline and then again 40 minutes post-treatment to assess if any changes had taken place.
Same as current
Not Provided
Not Provided
 
Cerebral Blood Flow Effects of Resveratrol and Piperine in Humans
Effects of Resveratrol Alone or in Combination With Piperine on Cerebral Blood Flow Parameters and Cognitive Performance in Humans
Resveratrol is associated with a plethora of physiological effects in humans, including modulation of cerebral blood flow, despite apparently poor bioavailability. This study investigated whether the physiological effects of resveratrol could be affected when co-supplemented with piperine, an alkaloid which may be able to enhance the bioavailability of resveratrol.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double Blind (Participant, Investigator)
Healthy
  • Dietary Supplement: Trans- resveratrol
    All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
  • Other: Placebo (silica)
    All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
  • Experimental: 250mg trans- resveratrol
    Interventions:
    • Dietary Supplement: Trans- resveratrol
    • Other: Placebo (silica)
  • Experimental: 250mg trans-resveratrol with 20mg piperine
    Interventions:
    • Dietary Supplement: Trans- resveratrol
    • Other: Placebo (silica)
  • Placebo Comparator: Placebo
    Interventions:
    • Dietary Supplement: Trans- resveratrol
    • Other: Placebo (silica)
Wightman EL, Reay JL, Haskell CF, Williamson G, Dew TP, Kennedy DO. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. Br J Nutr. 2014 Jul 28;112(2):203-13. doi: 10.1017/S0007114514000737. Epub 2014 May 7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
23
November 2010
November 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Between the ages of 18-35 years old
  • Healthy
  • Non-smoker

Exclusion Criteria:

  • Not proficient in English
  • Taking medication or herbal supplements
  • Pregnant or breast feeding
  • Heavy caffeine consumer
  • History of head trauma, migraines, learning difficulties, ADHD, gastrointestinal problems.
  • Food allergies of intolerances
Sexes Eligible for Study: All
18 Years to 35 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT01331382
22AB2
No
Not Provided
Not Provided
Emma Wightman, Northumbria university
Northumbria University
Not Provided
Principal Investigator: Emma L Wightman Northumbria University
Northumbria University
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP